Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aimmune Therap (AIMT)

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,688,929
  • Shares Outstanding, K 62,669
  • Annual Sales, $ 0 K
  • Annual Income, $ -210,750 K
  • 60-Month Beta -0.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.03
  • Number of Estimates 5
  • High Estimate -0.92
  • Low Estimate -1.11
  • Prior Year -0.95
  • Growth Rate Est. (year over year) -8.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.20 +8.73%
on 10/23/19
29.68 -7.68%
on 11/08/19
+2.25 (+8.95%)
since 10/18/19
3-Month
18.94 +44.67%
on 08/27/19
29.68 -7.68%
on 11/08/19
+6.00 (+28.04%)
since 08/19/19
52-Week
16.95 +61.65%
on 07/11/19
29.68 -7.68%
on 11/08/19
+1.11 (+4.22%)
since 11/19/18

Most Recent Stories

More News
Aimmune to Participate in Three Upcoming Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team...

AIMT : 27.40 (+1.67%)
Watch for Aimmune Therapeu to Potentially Rebound After Falling 2.63% Yesterday

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $27.46 to a high of $28.24. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of...

AIMT : 27.40 (+1.67%)
New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented new data showing that a strong clinical history,...

AIMT : 27.40 (+1.67%)
Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented results from two new surveys that examined the...

AIMT : 27.40 (+1.67%)
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral...

AIMT : 27.40 (+1.67%)
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the results from a new analysis showing consistent...

AIMT : 27.40 (+1.67%)
Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and nine...

AIMT : 27.40 (+1.67%)
Aimmune Therapeutics: 3Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Wednesday reported a loss of $64.5 million in its third quarter.

AIMT : 27.40 (+1.67%)
17.8% Return Seen to Date on SmarTrend Aimmune Therapeu Call (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on September 11th, 2019 at $24.73. In approximately 2 months, Aimmune Therapeu has returned 17.83% as of today's recent price of $29.14....

AIMT : 27.40 (+1.67%)
Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that members of the Aimmune executive management...

AIMT : 27.40 (+1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade AIMT with:

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Key Turning Points

2nd Resistance Point 28.07
1st Resistance Point 27.73
Last Price 27.40
1st Support Level 27.03
2nd Support Level 26.67

See More

52-Week High 29.68
Last Price 27.40
Fibonacci 61.8% 24.82
Fibonacci 50% 23.32
Fibonacci 38.2% 21.81
52-Week Low 16.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar